meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 2nd line (L2)
1
myofibroblastic tumors
neurofibroma
neutropenia
osteosarcoma
ovarian cancer (OC)
9
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab alone
avelumab plus pegylated liposomal doxorubicin
avelumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
olaparib
rucaparib
target therapy
multikinase inhibitor
nintedanib
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs pegylated liposomal doxorubicin
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded